About
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others.
Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of infection.
As of December 2025, we hold 68 issued and 29 pending patent applications for our products and technologies, with coverage in major pharmaceutical markets.
Lakewood-Amedex Biotherapeutics Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Live Market Snapshot
Real-time price and trading activity
USD · NASDAQ:NASDAQ:LABT
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | $2.83 | $2.83 | $1.92 | $1.96 | $1.96 | -0.87 | 406,000 |
| 2026-05-13 | $3.15 | $3.21 | $2.95 | $2.95 | $2.95 | -0.20 | 109,800 |
| 2026-05-12 | $3.12 | $3.32 | $3.12 | $3.22 | $3.22 | +0.10 | 224,600 |
| 2026-05-11 | $3.14 | $3.18 | $3.11 | $3.16 | $3.16 | +0.02 | 149,100 |
| 2026-05-08 | $3.25 | $3.26 | $2.93 | $3.10 | $3.10 | -0.15 | 152,000 |
| 2026-05-07 | $3.17 | $3.40 | $3.17 | $3.30 | $3.30 | +0.13 | 367,700 |
| 2026-05-06 | $2.93 | $3.28 | $2.93 | $3.13 | $3.13 | +0.20 | 287,800 |
| 2026-05-05 | $2.91 | $3.25 | $2.91 | $3.10 | $3.10 | +0.19 | 398,700 |
| 2026-05-04 | $2.77 | $3.30 | $2.77 | $3.26 | $3.26 | +0.49 | 820,600 |
| 2026-05-01 | $4.22 | $4.61 | $3.14 | $3.43 | $3.43 | -0.79 | 46,400,900 |
| 2026-04-30 | $3.51 | $3.55 | $2.58 | $2.66 | $2.66 | -0.85 | 307,000 |
| 2026-04-29 | $3.45 | $3.86 | $3.32 | $3.59 | $3.59 | +0.14 | 170,000 |
| 2026-04-28 | $3.63 | $4.04 | $3.14 | $3.89 | $3.89 | +0.26 | 276,800 |
| 2026-04-27 | $5.75 | $6.06 | $3.60 | $3.66 | $3.66 | -2.09 | 580,800 |
| 2026-04-24 | $8.65 | $9.40 | $7.01 | $7.35 | $7.35 | -1.30 | 5,211,100 |
| 2026-04-23 | $8.00 | $9.82 | $5.75 | $8.65 | $8.65 | +0.65 | 137,600 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 424B4 | May 14, 2026 | Prospectus |
| EFFECT | May 13, 2026 | Notice of Effectiveness |
| S-1 | May 1, 2026 | General form for registration of securities under the Securities Act of 1933 |
| 424B3 | Apr 30, 2026 | Prospectus |
| 8-K | Apr 28, 2026 | Current Report |
| 424B4 | Apr 23, 2026 | Prospectus |
| CERT | Apr 22, 2026 | Certification by an exchange approving securities for listing |
| EFFECT | Apr 17, 2026 | Notice of Effectiveness |
| 8-A12B | Apr 17, 2026 | Registration of securities |
| S-1/A | Apr 6, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Doug Manion, M.D., FRCP (C)
Chairman of the Board
Kelvin Cooper, Ph.D.
Chief Executive Officer, SVP Research & Development, Director
Peter Ceccacci
Chief Financial Officer, VP Administration
Thomas Balzer, M.D., Ph.D.
Chief Medical Officer, SVP Clinical Development
Leonard J. DeRoma
Director
